Sotagliflozin is an S-glycosyl compound that is 1-thio-beta-L-xylopyranose in which the anomeric hydroxy group is replaced by a 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl group and the thiol is replaced by a methylsulfanediyl group. It is an inhibitor of SGLT1 and SGLT2 that is approved to reduce the risk of cardiovascular death, hospitalization ...

ChemSpider record containing structure, synonyms, properties, vendors and database links for sotagliflozin, 1018899-04-1, QKDRXGFQVGOQKS-CRSSMBPESA-N

Dual SGLT1/2 inhibitors (SGLT1/2i) such as sotagliflozin target both SGLT1 and 2 proteins. Sotagliflozin or vehicle was administered to diabetic Akimba mice for 8 weeks at a dose of 25...

The initial single-dose and multiple-dose studies of sotagliflozin (LX4211-1-101) performed in healthy subjects, showed the maximum 24 h UGE was 44g achieved at the 300mg dose, and further ...

Sotaglifozin is a sodium-glucose co-transporter 1 and 2 inhibitor that reduces both postprandial glucose and insulin levels by delaying intestinal glucose absorption, decreases gastric inhibitory polypeptide, and elevations in glucagon-like peptide and peptide yy levels are consistent with local inhibition of intestinal SGLT1. [5]

Based on evidence of efficacy in clinical studies, the FDA approved sotagliflozin (in May 2023) to reduce deaths and hospitalisations of patients with heart failure (or at risk of heart failure) with both preserved and reduced left ventricular ejection fraction.

Sotagliflozin is a dual sodium-glucose co-transporter 1 and 2 inhibitor that increases glucosuria and natriuresis in patients with type 2 diabetes mellitus (T2DM). However, the safety and...

Structure: Mol file KCF file DB search: Simcomp: Neighbor: Class: Antidiabetic agent DG02044 Hypoglycemic agent DG01794 SGLT2 inhibitor ... D10669 Sotagliflozin (USAN/INN) <US> SLC5A2 (SGLT2) D10669 Sotagliflozin (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products

Jan 17, 2024 · sotagliflozin: ChEBI ID CHEBI:229226: Definition An S-glycosyl compound that is 1-thio-β-L-xylopyranose in which the anomeric hydroxy group is replaced by a 4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl group and the thiol is replaced by a methylsulfanediyl group. It is an inhibitor of SGLT1 and SGLT2 that is approved to reduce the risk of ...

2D Structure. An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor.